AIR-POWER 200 MG
GUAIFENESIN : 200 MG · DIN 02229984 · ENZYMATIC THERAPY (CANADA) INC.
Health Canada status: CANCELLED POST MARKET
What is AIR-POWER?
AIR-POWER 200 MG contains GUAIFENESIN : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02229984, held by ENZYMATIC THERAPY (CANADA) INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 08-Aug-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02229984 |
|---|---|
| Brand name | AIR-POWER |
| Generic / active ingredient | GUAIFENESIN : 200 MG |
| Manufacturer | ENZYMATIC THERAPY (CANADA) INC. |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | R05CA03 GUAIFENESIN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 08-Aug-2002 |
What can be used instead?
Other Canadian products sharing ATC code R05CA03 GUAIFENESIN. 10 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BALMINIL EXPECTORANT (SUCROSE FREE) | 100 MG / 5 ML | SYRUP | TEVA CANADA LIMITED | MARKETED | DIN 00609951 |
| BENYLIN EXTRA STRENGTH CHEST CONGESTION & COLD | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02265427 |
| BENYLIN EXTRA STRENGTH MUCUS & PHLEGM | 15 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02320940 |
| BENYLIN EXTRA STRENGTH SORE THROAT & COUGH | 200 MG / 5 ML | SYRUP | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | MARKETED | DIN 02479869 |
| BRONCHOPHAN EXPECTORANT (SANS SUCROSE) | 100 MG / 5 ML | SYRUP | LABORATOIRE ATLAS INC | MARKETED | DIN 02121999 |
| BUCKLEY'S CHEST CONGESTION | 100 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02289164 |
| BUCKLEY'S MUCUS & PHLEGM | 100 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02346451 |
| MUCINEX CHEST CONGESTION | 600 MG | TABLET (IMMEDIATE AND EXTENDED RELEASE) | RB HEALTH (CANADA) INC. | MARKETED | DIN 02434725 |
| MUCUS & PHLEGM RELIEF EXTRA STRENGTH | 200 MG / 5 ML | SYRUP | CRLS | MARKETED | DIN 02534762 |
| ROBITUSSIN EXTRA STRENGTH MUCUS AND PHLEGM | 200 MG / 5 ML | SYRUP | HALEON CANADA ULC | MARKETED | DIN 02142783 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.